NASDAQ: STROSutro Biopharma Inc Stock
$3.77+0.14 (+3.86%)
Updated Apr 22, 2024
STRO Price
$3.77
Fair Value Price
N/A
Market Cap
$235.41M
52 Week Low
$2.01
52 Week High
$6.13
P/E
-2.12x
P/B
1.57x
P/S
1.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$153.73M
Earnings
-$106.79M
Gross Margin
100%
Operating Margin
-50.36%
Profit Margin
-69.5%
Debt to Equity
2.15
Operating Cash Flow
-$112M
Beta
1.44
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
STRO Overview
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STRO is good value based on its book value relative to its share price (1.57x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
STRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STRO due diligence checks available for Premium users.
Be the first to know about important STRO news, forecast changes, insider trades & much more!
STRO News
Valuation
STRO fair value
Fair Value of STRO stock based on Discounted Cash Flow (DCF)
Price
$3.77
Fair Value
-$0.14
Undervalued by
2,860.51%
STRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.12x
Industry
16.21x
Market
41x
STRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.57x
Industry
5.82x
STRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STRO's financial health
Profit margin
Revenue
$113.7M
Net Income
$31.1M
Profit Margin
27.3%
STRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
STRO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$470.7M
Liabilities
$321.1M
Debt to equity
2.15
STRO's short-term assets ($421.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STRO's short-term assets ($421.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$14.1M
Investing
-$23.5M
Financing
-$3.1M
STRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STRO vs Biotech Stocks
Sutro Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.